Recital 249, Decision_act (EU) 2004/104

In forcesince 27 Nov 2002

Basic amounts of the fines should therefore be set as follows:

–

Merck KgaA: EUR 9,5 million

–

Rhône-Poulenc Biochimie SA/Aventis Pharma SA: EUR 4,75 million.

3.3.5. Aggravating circumstances

3.3.5.1. Role of leader in the infringement